Fairvalue-Calculator Fairvalue-Calculator
EN DE

Great Novel Therapeutics Biotech & Medicals (7427) Fair Value & Analysis

Healthcare · TW · Market cap 1.8B TWD

Price39.95 TWD
Fair Value28.69 TWD
Upside-28.2%
Quality95/100
Evidence: Low Range 21.52 TWD – 35.86 TWD

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Great Novel Therapeutics Biotech & Medicals (7427) currently trades at 39.95 TWD, while our model-based Fair Value estimate is 28.69 TWD — implying the stock looks roughly 28.2% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

Great Novel Therapeutics Biotech & Medicals engages in the development of drugs for the treatment of advanced and refractory cancers in Taiwan. The company develops GNTbm-38, an epigenetic immune-activating drug independently developed by GNTbm for cancer immunotherapy; and GNTbm-TKI, a potent inhibitor of TYRO-3, AXL, c-MER, BTK, ROS1, NTRK2, MET, and VEGFR2 for immune regulation, tumor growth inhibition, metastasis and invasion suppresion, and anti-angiogenesis activity. It is also developing Kepida to treat HR+/her-2 advanced breast cancer and Peripheral T-cell lymphoma. The company was formerly known as GNT Biotech & Medicals Corporation. Great Novel Therapeutics Biotech & Medicals was incorporated in 2013 and is based in Taipei, Taiwan.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -84% Regeneron Pharmaceuticals, Inc (REGN) +109% UCB SA (UCB) -23% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +9% Alnylam Pharmaceuticals, Inc (ALNY) -64%

Frequently asked questions

Is Great Novel Therapeutics Biotech & Medicals (7427) undervalued?
As of Jun 24, 2026, our model estimates a fair value of 28.69 TWD versus a price of 39.95 TWD — about −28% (overvalued). Model-based estimate, not financial advice.
What is the fair value of 7427?
Our 21-model fair value for Great Novel Therapeutics Biotech & Medicals is 28.69 TWD (as of Jun 24, 2026), built from audited fundamentals. The current price is 39.95 TWD.
What is the quality score of 7427?
Great Novel Therapeutics Biotech & Medicals has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.